There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease.
- Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication
- Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research
- Summarizes the latest insights into how immune escape defines an essential trait of cancer
- Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression
Basic, translational, and clinical cancer researchers as well as practicing oncologists and their patients
Part I: Principles of Cancer Immunobiology Introduction Cancer Immunoediting: From Immune Surveillance to Immune Escape Immunosurveillance: Innate and Adaptive Anti-Tumor Immunity Cytokine Regulation of Immune Tolerance to Tumors Immunological Sculpting: Natural Killer Cell Receptors and Ligands Immune Escape: Immunosuppressive Networks
Part II: Cancer Therapeutics Cytotoxic Chemotherapy in Clinical Treatment of Cancer Targeted Therapeutics in Cancer Treatment Concepts in Pharmacology and Toxicology Cancer Immunotherapy: Challenges and Opportunities Cancer Vaccines
Part III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune Suppression Immunotherapy and Cancer Therapeutics: Why Partner? Immune Stimulatory Features of Classical Chemotherapy Dendritic Cells and Co-Inhibitory Molecules Regulatory T Cells in Tumor Immunity: Role of Toll-like Receptors Tumor-associated Macrophages in Cancer Growth and Progression Tumor-associated Myeloid-derived Suppressor Cells Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune Escape IDO in Immune Escape: Regulation and Therapeutic Inhibition Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation Summary: Future Questions
- No. of pages:
- © Academic Press 2007
- 4th June 2007
- Academic Press
- eBook ISBN:
- Hardcover ISBN:
Lankenau Institute for Medical Research, Wynnewood, PA, U.S.A.
Department of Oncology, SKCCC, Johns Hopkins University, Baltimore, MD, U.S.A.
This relatively compact book is a summary of contemporary thinking about cancer immunotherapy, with a focus on the relationship between tumors and the immune response of the host. The book is edited by authorities on tumor biology and cancer immunotherapy and reflects the nascent synthesis of these disciplines. The chapters are written by highly respected investigators, and the topics span much of the breadth and depth of this evolving field. The book seems designed to provide an overview for those who wish to immerse themselves in this field and who have a working knowledge of immunotherapy but rudimentary familiarity with cancer immunobiology and therapy. - The New England Journal of Medicine, April 2008